These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 890697)

  • 21. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The treatment of metastasizing hypernephroid (renal cell) carcinoma with medroxyprogesterone acetate (Clinovir) (author's transl].
    von Lieven H; Hahn D
    MMW Munch Med Wochenschr; 1977 Aug; 119(34):1089-92. PubMed ID: 408657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen therapy of epithelial ovarian cancer.
    Shirey DR; Kavanagh JJ; Gershenson DM; Freedman RS; Copeland LJ; Jones LA
    Obstet Gynecol; 1985 Oct; 66(4):575-8. PubMed ID: 4047546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy.
    Zidan J; Zohar S; Mijiritzky I; Kral S; Bilenca B
    Isr Med Assoc J; 2002 Aug; 4(8):597-9. PubMed ID: 12183859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chemo-hormonotherapeutic treatment of 20 cases of metastatic ovarian carcinoma].
    Gallo Curcio C; Casali A; Gianciotta A; Gionfra T; Rinaldi M; Terzoli L; Orofino G
    Clin Ter; 1979 Jul; 90(2):137-42. PubMed ID: 118841
    [No Abstract]   [Full Text] [Related]  

  • 29. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
    Morgan RJ; Doroshow JH; Leong L; Schriber J; Shibata S; Forman S; Hamasaki V; Margolin K; Somlo G; Alvarnas J; McNamara M; Longmate J; Raschko J; Chow W; Vasilev S; McGonigle K; Yen Y
    Bone Marrow Transplant; 2001 Nov; 28(9):859-63. PubMed ID: 11781646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormone receptors and endocrine therapy of renal carcinoma].
    Pizzocaro G; Piva L; Di Fronzo G; Ronchi E; Giongo A; Cozzoli A; Dormia E; Minervini S; Zanollo A; Fontanella U
    Ric Clin Lab; 1985; 15 Suppl 2():95-102. PubMed ID: 2937131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The protective effect of medroxyprogesterone acetate in patients with ovarian cancer treated with chemotherapy].
    Enzelsberger H; Sevelda P; Salzer H
    Gynakol Rundsch; 1988; 28 Suppl 2():195-7. PubMed ID: 2976722
    [No Abstract]   [Full Text] [Related]  

  • 34. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
    Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
    J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.
    Safra T; Groshen S; Jeffers S; Tsao-Wei DD; Zhou L; Muderspach L; Roman L; Morrow CP; Burnett A; Muggia FM
    Cancer; 2001 Jan; 91(1):90-100. PubMed ID: 11148564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
    Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
    Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE; Nagel GA; Blossey HC
    Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma].
    Castiglione M; Cavalli F
    Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1073-6. PubMed ID: 7423153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study.
    Aabo K; Pedersen AG; Haid I; Dombernowsky P
    Cancer Treat Rep; 1982 Feb; 66(2):407-8. PubMed ID: 6459846
    [No Abstract]   [Full Text] [Related]  

  • 40. [High-dosed gestagen therapy of the metastatic mammary carcinoma (author's transl)].
    Firusian N; Becher R
    Strahlentherapie; 1981 Dec; 157(12):808-12. PubMed ID: 7330909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.